<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030274</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2016_06</org_study_id>
    <nct_id>NCT03030274</nct_id>
  </id_info>
  <brief_title>The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients</brief_title>
  <acronym>PRELIEVE</acronym>
  <official_title>Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients With Reduced Ejection Fraction or in Heart Failure Patients With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate safety and efficacy of the Occlutech® AFR device in patients
      with HFrEF (Heart failure with reduced ejection fraction) and HFpEF (Heart failure with
      preserved ejection fraction)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Device Effects (SADE) within 3 month following implantation.</measure>
    <time_frame>0-3 month</time_frame>
    <description>Incidence of Serious Adverse Device Effects (SADE) following implantation such as:
device dislocation / embolization
damage to the tricuspid or mitral valve caused by the device
intractable arrhythmias caused by the device
any circumstances that require device removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Device Effects (SADE) between 3-12 month following implantation</measure>
    <time_frame>3-12 month</time_frame>
    <description>Incidence of all Serious Adverse Device Effects (SADE) following implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device placement</measure>
    <time_frame>0-12 month</time_frame>
    <description>Device placement in situ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left to Right shunt through the AFR device</measure>
    <time_frame>0-12 month</time_frame>
    <description>Evidence of Left to Right shunt through the AFR device</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure Low Output</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech AFR device</intervention_name>
    <description>Catheter-guided placement of an AFR device following balloon atrial septostomy.</description>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria. Each patient must fulfill ALL of the following criteria and details:

          1. Age ≥18 years

          2. NYHA-Class III or IV ambulatory

          3. Ongoing management of heart failure according to ESC (European Society of Cardiology)
             -guidelines during previous ≥6 months

          4. Symptomatic heart failure resulting in at least one hospitalization in the past 12
             months

          5. Absence of moderate valvular diseases who require specific therapy (as per ESC
             guidance)

          6. Control of arrhythmia with heart rate &lt;90bpm

          7. Life expectancy of at least 1 year

          8. The patient should have the ability to fluently speak and understand the language in
             which the study is being conducted

          9. Written, informed consent by the patient for participation in the study and agreement
             to comply with the follow-up schedule

         10. Patient has had a successful Balloon Atrial Septostomy (BAS) procedure and is in a
             stable hemodynamic state, as assessed by the investigator

             Data by echocardiography:

         11. LVEF ≥15% and ≤55%

         12. Elevated left ventricular filling pressure

         13. Transseptal catheterization and femoral vein access is determined to be feasible

        Exclusion Criteria:

          1. Local or generalized sepsis or other acute infection(s)

          2. Any coagulation disorder, if clinically relevant in the opinion of the operator.

          3. Allergy to nickel and/or titanium and/or nickel/titanium-based materials, if not
             medically manageable

          4. Allergy to anti-platelet, -coagulant, or -thrombotic therapy, if not medically
             manageable

          5. Intolerance to contrast agents, if not medically manageable

          6. Participation in another medical trial testing a therapy less than 30 days before the
             intended AFR implantation procedure

          7. Trans-oesophageal echocardiography and / or use of general anaesthetic is
             contraindicated

          8. Breast feeding women

          9. Pregnancy

         10. Occluded inferior vena cava access

         11. History of ASD and/or atrial septal repair or closure device in place

         12. Intracardiac thrombus

         13. Patients who has unstable and intractable angina pectoris

         14. Evidence of right heart failure defined as (by ECHO)

               -  Severe Right Ventricular Dysfunction

               -  Severe Right Ventricular Dilatation

               -  Severe pulmonary hypertension

         15. Active malignancy

         16. Severe valve disease, or implanted mechanical valve prosthesis

         17. Congenital heart defect

         18. Large PFO with significant atrial septal aneurysm

         19. Resting heart rate &gt;110 bpm

         20. Inability to perform 6-minutes walking test

         21. Clinically relevant thrombocytopenia, thrombocytosis, leukopenia, or anemia

         22. Symptomatic carotid artery disease

         23. Mitral valve stenosis

         24. Has any condition that, in the opinion of the Investigator, might interfere with the
             implantation, might affect the patients well-being thereafter or might interfere with
             the conduct of the study

         25. Systolic blood pressure of &gt;170 mmHg, despite medical therapy

         26. Severe lung disease (causing PHT with systolic PAP &gt;60)

         27. Pulmonary Hypertension (Systolic PAP &gt;60)

         28. TIA or stroke within the last 6 months

         29. Scheduled for heart transplantation

         30. Bleeding disorders

         31. Myocardial infarction or percutaneous intervention or CABG (all within the last 3
             month) or indication for a coronary intervention

         32. Resynchronization therapy started within the last 6 months

         33. Aneurysm of the septum

         34. Hypertrophied Inter Atrial Septum (IAS)

         35. Hypertrophic Cardiomyopathy (HCM) or infiltrative CM as cause of HF

         36. Thromboembolic events within the last 6 months

         37. Dialysis and renal insufficiency requiring dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Schöndorf</last_name>
    <phone>+49(0)3641 67 51 20</phone>
    <email>clinicaltrials@occlutech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Center Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horst Sievert, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

